As many factors associated with SASP are known to induce fibrosis in the kidney [e.g., TGF-β, CCN2 (also known as CTGF), interleukin (IL)-1, and IL-6] (Wang et al., 2017), targeting senescence might prove an effective alternative strategy for CKD treatment. Here, CCN2 is linked to chronic kidney disease.